Global Point of Care Test Market 2020 and Forecast 2021-2027

                                          
POC testing allows physicians to quickly make decisions and begin treatment. Point of care improves clinical care and increases throughput, benefiting both patients and clinical facilities.  Point of care simplifies procedures fewer (often automated) steps. There is little need to allocate specimens or store and transport samples, reducing the potential for contamination or deterioration.

Testing devices have been designed for point of care with reduced footprints and the ability to analyze a larger range of biomarkers, making them more flexible than machinery in the central laboratory. Portability and versatility have expanded POC testing’s capability; diagnoses are conducted in less traditional places, such as lower-income areas and under-served populations, rural regions, and areas with limited infrastructure.

Point-of-Care testing can be defined as the medical diagnostic testing performed outside the clinical laboratory near the place where the patient is receiving treatment. This type of testing is performed by non-laboratory personnel and the results are used for clinical decision making. The Point-of-Care tests have immense potential to improve global health and to eventually reduce public and national spending on health.

Global COVID-19 diagnostics market size is alone valued at USD 18.9 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 2.9.1% from 2021 to 2027. These tests are critical in the management of the ongoing COVID-19 pandemic for accurate diagnosis as well as for tackling the spread of the infection. Over 600 SARS-CoV-2 diagnostic tests are either approved or are in the development phase for clinical use.

Therefore, an increase in the need for developing diagnostic tests is anticipated to drive the market growth. The current status of lead COVID tests is toward rising capacity but mixed accuracy. For efficient and accurate COVID-19 diagnosis, clinicians need a portable or an on-site diagnostic test for real-time management of patients in minimal time. This has encouraged the adoption of Point-of-Care (POC) testing for diagnosis, primarily aimed at reducing the assay duration from hours to a few minutes.

The Pixel by LabCorp™ COVID-19 at-home kit is a molecular test, also known as a reverse polymerase chain reaction (RT-PCR) test or a nucleic acid amplification test (NAAT). This test detects the presence or absence of SARS-CoV-2, the virus that causes COVID-19. The average time to deliver results is around 24-48 hours from when the sample is received at the lab. They have a partnership with FedeEX.

Banglore-based biotechnology company Bione said it has launched a rapid antibody-based at-home screening test kit for COVID-19 that is capable of giving results within 5-10 minutes. The kit which is approved by the Indian Council of Medical Research (ICMR) will be deployed in the market after proper quality checks and assurance. The screening test kit is based on immunoglobulins- IgG and IgM- and delivers results in 5-10 minutes. The user has to clean their finger using an alcohol swab and use the lancet provided to prick finger . The cartridge provided reads the results from the blood sample thus obtained, within 5-10 minutes, the company said.

Following authorization from the FDA, two companies, Vault Health and 1Health.io (the parent company of Vitagene), announced plans to sell the saliva tests for at-home use under supervision from a doctor through telemedicine for Corona virus. Both tests are now available without telemedical approval.

The global Point of Care Test market is valued at xx million US$ in 2020 is expected to reach xx million US$ by the end of 2026, growing at a CAGR of xx% during 2021-2026.

This report focuses on Point of Care Test volume and value at the global level, regional level, and company level. From a global perspective, this report represents the overall Point of Care Test market size by analyzing historical data and future prospects. Regionally, this report focuses on several key regions: North America, Europe, China, and Japan.

At the company level, this report focuses on the production capacity, ex-factory price, revenue, and market share for each manufacturer covered in this report.

The following manufacturers are covered:


 	
ACON Laboratories Inc.
 	
Abaxis Inc.
 	
Abbott Laboratories Inc.
 	
Accriva Diagnostics
 	
AccuBioTech Co. Ltd.
 	
Acrongenomics
 	
Alere Inc.
 	
Alfa Scientific Designs
 	
Alpha Scientific
 	
Atlas Genetics Ltd.
 	
Beckman Coulter Inc.
 	
Becton
 	
Bio-Rad Laboratories
 	
Biomerica Inc.
 	
Dickinson and Company
 	
Instrumentation Laboratory
 	
Johnson & Johnson
 	
Medica Corporation
 	
Medtronic
 	
Nova Biomedical
 	
Opti Medical
 	
PTS Diagnostics
 	
Roche Diagnostics Limited
 	
Siemens AG
 	
Sienco Inc.
 	
bioMerieux

Segment by Type

 	
Glucose Monitoring Kits
 	
Blood Gas and Electrolyte Analyzers
 	
Pregnancy & Fertility Testing Kits
 	
Cardiac Markers
 	
Infectious Diseases Testing Kits
 	
Drug-of-Abuse Testing Kits
 	
COVID-19 Testing Kits
 	
Others

Segment by Application

 	
Hospital
 	
Clinics
 	
Ambulatory Care
 	
Home Healthcare
 	
Research Laboratory